Axon Therapies’ implant-free, catheter-based procedure aims to normalize volume balance, stop disease progression and improve patient heart failure symptoms.

Derived from an existing clinical procedure, splanchnic ablation for volume management (SAVM) using the Axon™ Ablation System enables targeted ablation of the overactive sympathetic nervous system, a key driver of worsening heart failure.

Axon, founded by proven medtech incubator Coridea, is funded by leading healthcare investors, including Deerfield Management, Action Potential Venture Capital, and a confidential strategic investor.